Ultragenyx (RARE) - Total Liabilities
Based on the latest financial reports, Ultragenyx (RARE) has total liabilities worth $1.52 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ultragenyx - Total Liabilities Trend (2011–2025)
This chart illustrates how Ultragenyx's total liabilities have evolved over time, based on quarterly financial data. See Ultragenyx current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Ultragenyx Competitors by Total Liabilities
The table below lists competitors of Ultragenyx ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LG Household & Healthcare
KO:051900
|
Korea | ₩1.44 Trillion |
|
Guangshen Railway Co Ltd
SHG:601333
|
China | CN¥8.07 Billion |
|
Pengxin International Mining Co Ltd
SHG:600490
|
China | CN¥1.77 Billion |
|
BREVILLE GROUP LTD
F:HDE
|
Germany | €507.50 Million |
|
Mando Corp
KO:204320
|
Korea | ₩3.18 Trillion |
|
Bird Construction Inc.
TO:BDT
|
Canada | CA$1.48 Billion |
|
HeiLongJiang Kingland Technology Co Ltd
SHE:000711
|
China | CN¥695.56 Million |
|
Asahi India Glass Limited
NSE:ASAHIINDIA
|
India | Rs42.00 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Ultragenyx's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ultragenyx stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ultragenyx's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ultragenyx (2011–2025)
The table below shows the annual total liabilities of Ultragenyx from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Billion | +29.31% |
| 2024-12-31 | $1.24 Billion | +2.10% |
| 2023-12-31 | $1.22 Billion | +1.90% |
| 2022-12-31 | $1.19 Billion | +98.88% |
| 2021-12-31 | $599.84 Million | -0.88% |
| 2020-12-31 | $605.18 Million | +25.63% |
| 2019-12-31 | $481.73 Million | +335.37% |
| 2018-12-31 | $110.65 Million | +3.12% |
| 2017-12-31 | $107.30 Million | +60.98% |
| 2016-12-31 | $66.65 Million | +134.04% |
| 2015-12-31 | $28.48 Million | +118.70% |
| 2014-12-31 | $13.02 Million | +36.50% |
| 2013-12-31 | $9.54 Million | +139.94% |
| 2012-12-31 | $3.98 Million | +167.56% |
| 2011-12-31 | $1.49 Million | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more